Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Phase 1

Completed

Brief Summary: To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in children from 3 months of age to \<18 years.

Detailed Description: This is a phase I, open-label, single-dose study. The study aims to characterize the pharmacokinetics of CAZ-AVI and assess its safety and tolerability following a single IV dose given to hospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection. This study will include 4 cohorts, each consisting of at least 8 evaluable pediatric patients, aged ≥3 months to \<18 years, who are hospitalized with infections.

Recruitment & Eligibility

Inclusion Criteria

Written informed consent will be obtained from parent(s) or other legally acceptable representative(s), and informed assent from patient (if age appropriate) will be obtained
Male or female children ages ≥3 months to <18 years.
Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed infection, and expected to require hospitalization until after the end of treatment (EOT) evaluations are completed.
If female and has reached menarche, or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient is practicing appropriate birth control or is sexually abstinent.
Likely to survive the current illness or hospitalization.
Sufficient intravascular access (peripheral or central) to receive study drug.

Exclusion Criteria

History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, other β-lactam antibiotics.
If female, currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test.
Receipt of a blood or blood component (e.g., red blood cells, fresh frozen plasma, platelets) transfusion during the 24-hour period before enrolment.
BMI outside the range (below the 5th percentile or above the 85th percentile) for height, age, and weight except for children <2 years of age.
Babies born prior to 37 weeks gestation (cohort 4 only).

Arm && Interventions

Group	Intervention	Description
CAZ-AVI	CAZ-AVI	This arm will include 4 cohorts. Patients will be stratified by age.

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic Parameters of Avibactam and Ceftazidime for Cohort 1 and 2: Cmax	Day 1	Key PK parameters are shown for cohorts 1 and 2. For cohorts 3 and 4 (where children were \<6 years of age), sparse sampling scheme was used for PK samples to limit the volume of blood required. PK parameters cannot be derived from these sparse PK samples without population PK analysis. Thus the PK is not described here, but will be reported in a separate population PK report.
Pharmacokinetic Parameters of Avibactam and Ceftazidime for Cohort 1 and 2: AUC	Day 1	Key PK parameters were prespecified to be calculated for cohorts 1 and 2. For cohorts 3 and 4 (where children were \<6 years of age), sparse sampling scheme was used for PK samples to limit the volume of blood required. PK parameters cannot be derived from these sparse PK samples without population PK analysis. Thus the PK is not described here, but will be reported in a separate population PK report.

Secondary Outcome Measures